VIR
Income statement / Annual
Last year (2024), Vir Biotechnology, Inc.'s total revenue was $74.21 M,
a decrease of 13.90% from the previous year.
In 2024, Vir Biotechnology, Inc.'s net income was -$521.96 M.
See Vir Biotechnology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$74.21 M |
$86.18 M |
$1.62 B |
$1.10 B |
$67.25 M |
$711.00 K |
$868.00 K |
$149.00 K |
| Cost of Revenue |
$478.65 M
|
$572.83 M
|
$620.97 M
|
$513.87 M
|
$0.00
|
$0.00
|
$100.23 M
|
$62.51 M
|
| Gross Profit |
-$404.44 M
|
-$486.65 M
|
$994.83 M
|
$581.54 M
|
$67.25 M
|
$711.00 K
|
-$99.36 M
|
-$62.36 M
|
| Gross Profit Ratio |
-5.45
|
-5.65
|
0.62
|
0.53
|
1
|
1
|
-114.47
|
-418.54
|
| Research and Development Expenses |
$506.50 M
|
$579.72 M
|
$474.65 M
|
$448.01 M
|
$302.41 M
|
$148.47 M
|
$100.23 M
|
$62.51 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$70.94 M
|
$37.60 M
|
$29.13 M
|
$21.69 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$70.94 M
|
$37.60 M
|
$29.13 M
|
$21.69 M
|
| Other Expenses |
-$323.77 M
|
-$382.06 M
|
-$312.89 M
|
-$287.21 M
|
-$9.12 M
|
-$7.38 M
|
-$212.00 K
|
$83.00 K
|
| Operating Expenses |
$182.73 M
|
$197.66 M
|
$161.76 M
|
$160.79 M
|
$364.23 M
|
$178.69 M
|
$119.56 M
|
$81.65 M
|
| Cost And Expenses |
$661.37 M
|
$770.49 M
|
$782.73 M
|
$674.66 M
|
$364.23 M
|
$178.69 M
|
$119.56 M
|
$81.65 M
|
| Interest Income |
$71.81 M
|
$86.99 M
|
$28.09 M
|
$439.00 K
|
$2.84 M
|
$8.51 M
|
$2.54 M
|
$638.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$14.56 M
|
$19.45 M
|
$6.78 M
|
$5.81 M
|
$5.44 M
|
$4.52 M
|
$2.76 M
|
$432.00 K
|
| EBITDA |
-$508.91 M |
-$641.64 M |
$839.85 M |
$426.56 M |
-$291.54 M |
-$173.46 M |
-$115.94 M |
-$81.07 M |
| EBITDA Ratio |
-6.86
|
-7.45
|
0.52
|
0.39
|
-4.34
|
-243.97
|
-133.57
|
-544.06
|
| Operating Income Ratio |
-7.91
|
-7.94
|
0.52
|
0.38
|
-4.42
|
-250.32
|
-136.74
|
-546.96
|
| Total Other Income/Expenses Net |
$64.06 M
|
$56.11 M
|
-$78.79 M
|
$129.05 M
|
-$1.63 M
|
$3.45 M
|
$2.33 M
|
$721.00 K
|
| Income Before Tax |
-$523.11 M
|
-$628.19 M
|
$754.28 M
|
$549.80 M
|
-$298.61 M
|
-$174.53 M
|
-$116.36 M
|
-$80.78 M
|
| Income Before Tax Ratio |
-7.05
|
-7.29
|
0.47
|
0.5
|
-4.44
|
-245.47
|
-134.06
|
-542.12
|
| Income Tax Expense |
-$1.15 M
|
-$13.08 M
|
$238.44 M
|
$21.22 M
|
$54.00 K
|
$154.00 K
|
-$480.00 K
|
-$10.92 M
|
| Net Income |
-$521.96 M
|
-$615.06 M
|
$515.84 M
|
$528.58 M
|
-$298.67 M
|
-$174.68 M
|
-$115.88 M
|
-$69.85 M
|
| Net Income Ratio |
-7.03
|
-7.14
|
0.32
|
0.48
|
-4.44
|
-245.69
|
-133.51
|
-468.81
|
| EPS |
-3.83 |
-4.59 |
3.89 |
4.07 |
-2.51 |
-1.62 |
-1.2 |
-10.02 |
| EPS Diluted |
-3.83 |
-4.59 |
3.83 |
3.96 |
-2.51 |
-1.62 |
-1.2 |
-10.02 |
| Weighted Average Shares Out |
$136.25 M
|
$134.13 M
|
$132.61 M
|
$129.88 M
|
$119.16 M
|
$107.65 M
|
$96.91 M
|
$6.97 M
|
| Weighted Average Shares Out Diluted |
$136.25 M
|
$134.13 M
|
$134.81 M
|
$133.44 M
|
$119.16 M
|
$107.65 M
|
$96.91 M
|
$6.97 M
|
| Link |
|
|
|
|
|
|
|
|
